iRadimed Q4 Adjusted EPS $0.39 Misses $0.40 Estimate, Sales $17.45M Beat $17.33M Estimate
Portfolio Pulse from Benzinga Newsdesk
iRadimed (NASDAQ:IRMD) reported Q4 adjusted EPS of $0.39, missing the $0.40 estimate, but sales of $17.45M exceeded the $17.33M estimate. This represents a 21.88% increase in earnings and a 17.42% increase in sales from the same period last year.
February 08, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
iRadimed reported a slight miss on Q4 EPS estimates but exceeded sales expectations, showing significant year-over-year growth in both earnings and sales.
The slight miss in EPS might concern some investors, potentially putting downward pressure on the stock. However, the beat on sales and the significant year-over-year growth in both earnings and sales could counterbalance this, suggesting a neutral short-term impact. The company's performance indicates underlying strength, which could support investor confidence.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100